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ABSTRACT
L-Dopa-D-phenylglycine was synthesized in this laboratory as L-dopa derivative for improving its intestinal absorption. As designed
for transport through the intestine via oligopeptide transporter (PepT1), the competition of this dipeptide with known substrates for PepT1
in brush-border membrane vesicle (BBMV) was investigated. At the presence of L-Glycinyl-L-proline (L-Gly-L-Pro), L-Glycinyl-Lphenylalanine (L-Gly-L-Phe) or cephradine, the uptake of L-dopa-D-phenylglycine in BBMV was reduced to 54.1 ± 4.5%, 57.6 ± 5.2% or
62.9 ± 10.2%, respectively. The inhibition by these dipeptides and the tripeptide mimetic amino-β-lactam was significantly higher than by
amino acids L-Phenylalanine (L-Phe) or L-dopa. The results suggested that the intestinal H+-coupled PepT1 was involved in the uptake of
L-dopa-D-phenylglycine. The steady state plasma concentrations of L-dopa-D-phenylglycine and L-dopa in rats after a single pass in-situ
jejunal perfusion with 0.1 mM perfusate were 104.0 ± 12.90 µg/mL and 1.24 µg/mL respectively. L-Dopa-D-phenylglycine demonstrated
a 50.1 fold higher plasma concentration, in terms of molar ratio, than that of L-dopa. D-Phenylglycine was proved to be a satisfactory moiety for the improvement of L-dopa absorption in the intestine.
Key words: L-Dopa-D-phenylglycine, dipeptide mimetics, PepT1, intestinal absorption

INTRODUCTION
L-Dopa has long been used as a prodrug of dopamine in
the treatment of Parkinson's disease(1,2). However, clinically
this drug illustrated wide range of inter- and intra-patient
variations in the rate and extent of absorption(3,4). The variation of oral bioavailability due to its interaction with food is
in part attributed to its complicated absorption through amino
acid transport systems with amino acids in the diet(5,6). A
rational approach in improving the oral bioavailability of Ldopa is thus to prevent this drug from being absorbed via
these routes.
Studies revealed the existence of H+-coupled oligopeptide transporter (PepT1) in brush-border membrane of duodenum, jejunum and ileum of the small intestine(7,8). This
transporter was responsible for the absorption of dipeptide
mimetic angiotensin converting enzyme (ACE)
inhibitors(9,10), and orally absorbable tripeptide mimetic
amino-β-lactams(11-19). Based on the thought that D-phenylglycine is the common moiety in the molecules of orally
absorbable amino- β -lactams, we proved that D-phenylglycine significantly increased the uptake of α-methyldopa
in BBMV and might be a feasible delivery tool for transporting drugs of poor bioavailability through the intestine via
PepT1(20).We further used D-phenylglycine to prepare a
series of tripeptide mimetic L-dopa derivatives as dopamine
prodrugs(21). In this report we describe the synthesis of a
* Author for correspondence. Tel: 03-3273023;
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dipeptide L-dopa-D-phenylglycine and its transport via
PepT1. The intestinal absorption of this dipeptide in rats with
that of L-dopa is also compared.

MATERIALS AND METHODS
I. Materials and Instruments
Chemicals, reagent grade for synthesis and analytical
grade for biological studies, were from Sigma (Saint Louis,
Missouri, U. S. A), E. Merck (Darmstadt, Germany), Aldrich
(Milwaukee, Wisconsin, U. S. A) and Wako (Osaka, Japan).
Melting points were determined in Buchi 510 capillary melting point apparatus and were uncorrected. IR spectra were
determined on a Perkin-Elmer 1760 FT-IR instrument
(Shelton, Connectitut, U. S. A). Proton NMR spectra were
determined on a Bruker 80 MHz or Bruker 400 MHz spectrometer (Madison, Wisconsin, U. S. A) with chemical shifts
recorded in parts per million relative to tetramethylsilane.
Mass and high-resolution mass (HRMS) were measured on
Finnigan MAT 4510 and JEOL JNS-D300 spectrometer
respectively. Branson Sonifier 450 sonicator, Kubota 2010
and Eppendorf 5415C centrifuge, Model 905 incubator
(Cherng Huei Instrument Co.) and Ystral Laboratory series
x10/20 Homogenizer were used in the preparation of intestinal mucosal suspension. Osmolarity of test solutions was
determined with Wescor 5500 vapor pressure osmometer
(Wescor Company, Logan, UT, U.S.A.). High performance
liquid chromatography system used in the assay of biological
samples consisted of an autosampler (AS950, Jasco, Tokyo,
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Japan), a Model 600E (Waters, Milford, Massachussetts,
U.S.A.) solvent delivery pump, a Model LC-4C electrochemical detector with a glassy-carbon electrode (Bioanalytical
Systems, Inc., West Lafayette, Indiana, U.S.A.), and an integrator (Macintegrator I, Curperpino, San Francisco, U. S.
A.).
II. Animals
Male Wistar rats weighing 200-350 g were used in
preparing intestinal mucosal suspension and in intestinal perfusion studies. Animals were housed in a 12 hr light/dark
with 21 ± 2˚C constant temperature environment prior to
study. The rats were fasted for 18 hr before the experiment.
Water was supplied ad libitum.
III. Synthesis
L-N(Boc)-dopa-D-phenylglycine benzyl ester: A solution of L-N(Boc)-dopa prepared according to Bloom et
al.(22), D-phenylglycine benzyl ester hydrochloride(23), dicyclohexylcarbodiimide (DCC), hydroxybenztriazole (HOBt)
and sodium carbonate in molar ratio 1.0:1.0:1.0:1.1:1.1 in
dioxane was stirred at room temperature for 16 hr until the
reaction was judged complete by TLC. The solid precipitate
was filtered off, the filtrate was concentrated in vacuo and the
residue was partitioned between ethyl acetate and aqueous
potassium hydrogen sulfate (KHSO4) solution (5%). The
combined ethyl acetate solution was dried over anhydrous
magnesium sulfate and filtered. The filtrate was concentrated
in vacuo. The solid residue was chromatographed to afford
L-N(Boc)-dopa-D-phenylglycine benzyl ester (yield 65%) as
colorless solid; mp 69-70˚C; IR (KBr) nmax 3500-3300 (br),
1736, 1719, 1702, 1686 cm-1; 1HNMR (400 MHz, CDCl3)
δ1.36 (s, 9H, t-butyl ), 2.79-2.90 (m, 2H, catechol-CH2-),
4.37 (br, 1H, CONH), 5.03-5.20 (m, 3H, Ph-CH+Ph-CH2-),
5.52 (m, 1H, CH), 6.42-6.70 (m, 3H, catechol Hs), 7.21-7.26
(m, 10H, Ph-Hs) ppm.
L-Dopa-D-phenylglycine: A solution of L-N(Boc)dopa-D-phenylglycine benzyl ester in trifluoroacetic acid
and dichloromethane (1:1, v/v) was stirred at room temperature for 3 hr. The volatile components were removed in vacuo
and n-hexane was added to facilitate precipitation. A
methanolic solution of the L-dopa-D-phenylglycine benzyl
ester intermediate was subjected to hydrogenolysis in the
presence of palladium hydroxide in charcoal (Pd(OH)2/C
containing 20% of Pd) under hydrogen (14.7 psi). When the
reaction was judged complete by TLC, the catalyst was
removed by filtration and the solvent was evaporated to dryness. The crude product was purified by reversed-phase
MPLC (Lobar RP-18, 40-63 mm) using a solvent system
containing aqueous trifluoroacetic acid (0.1%) and MeOH
as the mobile phase to give the desired L-dopa-D-phenylglycine (yield 59%) as colorless solid; mp 216˚C (dec.); IR
(KBr) nmax 3500-3300 (br), 1661, cm-1; 1H NMR: (400 MHz,
D2O+TFA): δ 2.72-2.90 (m, 2H, -CH2-), 5.30 (s, 1H, Ph-CH), 6.34-6.62(m, 3H, catechol H), 7.21 (s, 5H, Ph H) ppm;

HRMS (FAB-) m/z 329.1134 (M-H)– (calcd for C17H17N2O5
m/z 329.1137).
IV. BBMV Uptake Studies
Brush-border membrane vesicles (BBMV) were prepared using a magnesium precipitation method and protein
content was determined(24). The purity of BBMV was indicated by measuring the activity of the marker enzymes, alkaline phosphatase and aminopeptidase. Generally, these two
enzymes were enriched 8-21 fold in the preparation. The
activity of Na+, K+-ATPase, the marker enzyme of basolateral membranes, was very small. Normal function of BBMV
was confirmed by measuring the uptake of D-glucose. In the
presence of Na+ gradient ([Na+]in < [Na+]out), an overshoot
phenomenon of glucose uptake with peak values of 9-11
times the equilibrium was routinely observed. The membrane
vesicles were preloaded in the buffer solution containing 300
mM mannitol and 16 mM HEPES/Tris (16 mM, pH 7.4)
before the experiment. For studies on the effect of osmolarity upon drug uptake, 300, 450, 600, and 800 mM of mannitol
were used. The uptake of test compounds in BBMV was
measured by a rapid filtration technique. A BBMV preparation (20 mL containing approximately 20 mg protein / mL)
was added into 200 mL of a reaction buffer comprising mannitol (300 mM), HEPES/Tris buffer (25 mM adjusted to pH
7.4 by adding MES) and the test drug solutions (1-2 mM).
After incubation at room temperature for acquired time, an
ice-cold stop solution (1.5 mL) containing NaCl (150 mM)
and HEPES / Tris (16 mM, pH 7.4) was added and the solution was filtered through a filter paper (Whatman WCN, 0.45
mm pore size, 2.5 cm diameter) under a vacuum. The filter
paper was washed twice with 3 mL of the same stop solution.
The drugs remaining on the filter paper were extracted with
0.5 mL of 0.01 M aqueous HCl solution by virtue of a vortex
motion. The solution (100 mL) was injected onto the HPLC
column. The drug bound on the filter paper was determined
for correction in different runs using preparations without
BBMV added.
V. Degradation of L-Dopa-D-phenylglycine in Intestinal
Mucosa Suspension
Mucosa suspension was prepared from the intestine of
male Wistar rats according to the method of Hu et al and was
stored in an ice bath before use(25). Degradation studies were
conducted immediately after the mucosa suspension was prepared. A methanolic solution (100 µL) of the test compound
(1 mg/mL) was diluted with an isotonic mannitol buffer solution (pH 6.5, 2.4 mL) as the stock solution. This stock solution (1000 µ L) was mixed with the mucosal suspension
(1000 µL). The mixture was incubated in a water bath at
37˚C and subjected to sampling at intervals between zero to
60 minutes. Each sampled solution (200 µL) was denatured
with 0.8 mL of MeOH and centrifuged at 6600 g for 5 minutes. Each of the supernatant (20 -100 µL) was subjected to
HPLC assay.
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VI. In Situ Rat Perfusion
Preparation of jejunal segments and the perfusion solutions followed the procedure of Lu et al(26). In order to simulate the intestinal microclimate, the experiments were performed at pH 6.0 phosphate buffer solution. To maximize the
absorption and to prevent the test compounds from being oxidized during perfusion, 0.02% ascorbic acid was added as an
antioxidant and nitrogen gas was bubbled through for 10 min
before each experiment. Concentration of the test compounds
in the perfusion solutions was 0.1 mM. The entire surgical
area of the jejunal segment was covered with parafilm to
minimize temperature reduction through evaporation. Tubing
and syringes were covered with aluminum foil to retard the
oxidation of testing compounds. Perfusion solution was
pumped through the jejunal segment at a flow rate of 0.2
mL/min by a syringe pump (Stoelting, KD Scientific,
Pennsylvania, U.S.A.). The jejunal segment was prewashed
with drug-free buffer for 10 min before the drug solution was
pumped in. Outlet tubing samples were collected every 10
min for 6 collection periods after water and solute transport
reached steady-state. After 90 min of perfusion, blood samples were centrifuged at 1415 g for 10 min. The plasma sample separated was stored at –20˚C before analysis. The samples were filtered through 0.2 µm membrane filters before
injecting into HPLC system.
VII. Chromatography
Samples from BBMV uptake experiments, stability
studies and the perfusion experiments were assayed in HPLC
coupled with an electrochemical detector (0.75 V; filter 0.1
Hz). L-Dopa-D-phenylglycine was eluted in a Lichrospher
RP-18 column (5 mm, 250 mm × 4 mm, E. Merck, Germany)
with a solvent system comprising acetonitrile and ammonium
phosphate buffer (0.1M, pH 3.3) at a ratio of 2:8 and sodium
dodecyl sulfate (0.05%, w/v) at a flow rate of 1.2 mL/min. LDopa was eluted in a Spheris S5 SCX column (5µm, 250 x
4.6 mm, Spherisob, USA) with a solvent system comprising
1.84 mM tetrabutylammonium hydrogen sulfate, 1.04 mM
sodium dodecylsulfate in 7.5 % (v/v) phosphate buffer (pH
2.0, 0.1 M) at a flow rate of 1.5 mL/min. Isoproterenol and

VIII. Data Analysis
Data analysis were performed on Visual dBase and
SPSS/PC+ and were represented as mean ± S.D. for n experiments. Treatment differences were evaluated by paired
Student’s t-test.

RESULTS AND DISCUSSION
Preparation of L-N(Boc)-dopa-D-phenylglycine benzyl
ester from L-N(Boc)-dopa and D-phenylglycine benzyl ester
followed general procedures of peptide synthesis using dicyclohexylcarbodiimide (DCC) as coupling reagent and 1hydroxybenzotriazole (HOBt) for the prevention of epimerization. Removal of Boc and benzyl protecting groups by
treatment with trifluoroacetic acid followed by catalytic
hydrogenolysis in the presence of Pd(OH)2 lead to L-dopaD-phenylglycine (Scheme 1).
Typical HPLC chromatograms of L-dopa-D-phenylglycine and L-dopa from plasma samples are shown in
Figure 1. Recovery of drugs was estimated by comparison of
peak areas in drug-free plasma extracts spiked with standard
solutions. The plasma recovery rates were 74.9% ± 3.0 (n =
3) and 82.0% ± 5.6 (n = 3), respectively, for L-dopa-Dphenylglycine and L-dopa. Replicate standards (n = 6) were
analyzed to assess the intra-day and inter-day variability of
the assay and the precision expressed as coefficient of variation (CV), as well as accuracy expressed as relative errors
(RE) were calculated. The standard curve of L-dopa-Dphenylglycine was linear over the plasma concentration
range of 0.1 to 30 µg/mL (r2 = 0.998) with the limit of quantitation (LOQ) at 0.1 µg/mL. The overall intra-day and interday accuracy (RE) were between –7.44 and +4.74% and the
CV were less than 20%. The standard curve of L-dopa was
linear over the plasma concentration range of 0.05 µg/mL to
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dihydroxyl-benzylamine were used as internal standards for
L-dopa-D-phenylglycine and L-dopa, respectively. The
retention time of L-dopa-D-phenylglycine and L-dopa were
8.420 and 3.585 min, respectively. The precision and accuracy of assay methods were validated by intra-day and interday analysis of serum standards over a period of 6 days.

iii
N(Boc)-L-dopa R1=Boc

L-dopa-D-phenylglycine R1=R2=H

i. (Boc)2O/Na2CO3 / 50% THF(aq) / N2 ii.D-phenylglycine benzyl ester / DCC / HOBt / Na2CO3/
dioxane iii. (a) TFA / CH2Cl2; (b) H2 / Pd(OH)2 / MeOH

Scheme 1. Synthesis of L-dopa-D-phenylglycine.

R1=Boc, R2=benzyl
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Figure 1. HPLC chromatograms of plasma samples containing (a) L-dopa-D-phenylglycine (retention time 8.42 min) with isoproterenol (retention
time 5.79 min) as internal standard or (b) L-dopa (retention time 5.49 min) with dihydroxyl-benzylamine (retention time 3.58 min) as internal standard.
1.1
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120%
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Figure 2. The uptake of L-dopa-D-phenylglycine in BBMV was significantly reduced to 54.1 ± 4.5%, 57.6 ± 5.2% and 62.9 ± 10.2%,
respectively, in the presence of L-Gly-L-Pro, L-Gly-L-Phe or cephradine (p<0.05), while no significant reduction of the uptake of L-dopaD-phenylglycine was observed while L-Phe or L-dopa was present.

2.5 µg/mL (r2 = 0.995) with the limit of quantitation (LOQ)
at 0.05 µg/mL. The overall intra-day and inter-day RE were
between –9.23 and +8.31% with CV less than 14%.
The H+-coupled transport system PepT1 exists in brushborder membrane of duodenum, jejunum and ileum of the
small intestine(8). Studies of the transport of L-dopa-Dphenylglycine and L-dopa via PepT1 was thus conducted by
measuring their uptake in the brush-border membrane vesicle
(BBMV) prepared from isolated jejunum segment of rat
intestine according to literature method. As L-dopa-Dphenylglycine was designed to be absorbed in the intestine
via PepT1, its transport via this transporter was investigated
by the competition of BBMV uptake with L-Gly-L-Pro, LGly-L-Phe and cephradine, known to be transported via this
transport system(14,17). This compound was incubated in
BBMV with the presence of ten times the molar ratio of LPhenylalanine (20 mM), L-dopa (20 mM), L-Gly-L-Pro (20
mM), L-Gly-L-Phe (20 mM) or cephradine (20 mM), respectively. No significant inhibition on the BBMV uptake of Ldopa-D-phenylglycine was observed when it was incubated

0.4
0

30

60
Time (min)

90

Figure 3. The degradation of L-dopa-D-phenyglycine (--) in rat
intestinal mucosa suspension in comparison with L-Gly-L-Phe (--).
The recovery of each test compound was presented as remaining ratio
(mean ± S.D.) of 3 experiments.

with amino acids L-Phe or L-dopa. On the other hand, its
uptake was reduced to 54.1 ± 4.5%, 57.6 ± 5.2% and 62.9 ±
10.2%, respectively, in the presence of L-Gly-L-Pro, L-GlyL-Phe or cephradine (Figure 2). The inhibition was significantly higher than by L-Phe. The results suggested that the
intestinal H+-coupled PepT1 was involved in the uptake of
the dipeptide mimetic L-dopa-D-phenylglycine.
Stability of L-dopa-D-phenylglycine in rat intestine was
determined prior to the absorption study by virtue of measuring its degradation in a mucosal preparation isolated from rat
intestine(3). In order to simulate the intestinal microclimate
pH, test compounds, L-dopa-D-phenylglycine or L-Gly-LPhe for comparison, was incubated with the mucosal suspension in a pH 6.0 isotonic buffer solution. Samples were withdrawn for analysis in HPLC at time intervals between zero
and 90 min of incubation. L-Gly-L-Phe, used as a reference
to ensure the enzymatic activity of the mucosal preparation,
degraded rapidly with only 19% of recovery after 2 min of
incubation. L-Dopa-D-phenylglycine on the other hand was
fairly stable with more than 85% of recovery after 90 min of
incubation, indicating its stability in the intestine (Figure 3).
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Table 1. Dimensionless membrane permeabilities (Pm*) and steady state plasma concentrations of L-dopa-D-phenylglycine and L-dopa in rats
measured by in situ single-pass jejunal perfusion
Compounda
No. of Experiments
Pm*
plasma conc.b (µg/mL)
molar ratioc relative to L-dopa
L-dopa-D-phenylglycine
4
1.32 ± 0.33
104.0 ± 12.9
50.1
L-dopa
3
0.94 ± 0.10
1.24d
1.0
a Concentration of the perfusate of each compound was 0.1 mM.
b Data presented are mean ± S.D. of n experiments.
c Plasma concentration in molar ratio relative to L-dopa.
d L-Dopa was detected in one of three test rats. It was below detection limit in the other two rats.

The intestinal absorption of L-dopa-D-phenyglycine
and L-dopa were compared by measuring the steady-state
plasma concentration in rats by in situ single-pass jejunal
perfusion. The steady-state plasma concentration of the perfused drugs was monitored. Amidon’s dimensionless membrane permeability (Pm*) was also measured as an indication
for drug disappearance from the intestine(26). According to
the theoretical analysis of Johnson and Amidon, Pm* calculated from experimental steady-state perfusion data, is the
fundamental parameter for measuring oral bioavailability of
drugs, assuming that chemical stability, first-pass metabolism and solubility/dissolution are not rate controlling factors(27,28). With equal molar concentration of compounds
perfused, L-dopa-D-phenyglycine demonstrated higher Pm*
than that of L-dopa (p<0.025, Table 1). The plasma concentration of L-dopa-D-phenyglycine (104.0 ± 12.90 µg/mL)
was 50.1 fold, in terms of molar ratio, higher than that of Ldopa (1.24 µg/mL).

CONCLUSION
D-Phenylglycine was designed as a delivery tool for
transporting L-dopa through the intestine via intestinal
PepT1 transporter. In an inward proton gradient, dipeptides
L-Gly-L-Pro, L-Gly-L-Phe, and tripeptide mimetic amino-βlactam cephradine inhibited the BBMV uptake of this dipeptide, suggesting that this compound was taken up in the intestine by PepT1. This dipeptide was better absorbed than Ldopa in rats as the steady-state plasma concentration was
measured by in situ single-pass jejunal perfusion. The
approach to use D-phenylglycine as a drug delivery tool for
improving the intestinal absorption of L-dopa was proved
successful. Biotransformation and pharmacokinetic profiles
from this dipeptide prodrug to dopamine and the antiParkinsonism activity after oral administration of this prodrug need to be further investigated.
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